Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 26 | 2020 | 1127 | 3.370 |
Why?
|
Brain Ischemia | 15 | 2020 | 399 | 2.690 |
Why?
|
Leukoaraiosis | 6 | 2019 | 44 | 1.280 |
Why?
|
Thrombolytic Therapy | 8 | 2020 | 184 | 1.270 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2012 | 204 | 0.870 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 8 | 0.780 |
Why?
|
Tissue Plasminogen Activator | 5 | 2020 | 125 | 0.750 |
Why?
|
Fibrinolytic Agents | 3 | 2020 | 163 | 0.660 |
Why?
|
Amyloid beta-Peptides | 3 | 2015 | 286 | 0.660 |
Why?
|
Quality of Health Care | 2 | 2014 | 513 | 0.640 |
Why?
|
Sleep | 2 | 2015 | 215 | 0.620 |
Why?
|
Atrial Fibrillation | 4 | 2020 | 805 | 0.600 |
Why?
|
Amnesia | 2 | 2015 | 9 | 0.580 |
Why?
|
Anticoagulants | 4 | 2019 | 480 | 0.580 |
Why?
|
Cerebral Infarction | 3 | 2015 | 76 | 0.480 |
Why?
|
Health Status Disparities | 1 | 2016 | 137 | 0.470 |
Why?
|
Humans | 57 | 2024 | 59366 | 0.460 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2006 | 26 | 0.450 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2007 | 211 | 0.440 |
Why?
|
Heparin | 2 | 2006 | 111 | 0.430 |
Why?
|
Blood Pressure | 1 | 2015 | 495 | 0.420 |
Why?
|
Aspergillosis | 4 | 1994 | 40 | 0.410 |
Why?
|
Aged | 26 | 2020 | 13405 | 0.390 |
Why?
|
Neuroimaging | 2 | 2014 | 143 | 0.380 |
Why?
|
Arterial Occlusive Diseases | 1 | 2012 | 71 | 0.380 |
Why?
|
Cognitive Dysfunction | 1 | 2015 | 309 | 0.370 |
Why?
|
Male | 36 | 2020 | 27742 | 0.370 |
Why?
|
Sex Characteristics | 1 | 2012 | 197 | 0.360 |
Why?
|
Ischemic Attack, Transient | 2 | 2019 | 90 | 0.350 |
Why?
|
Severity of Illness Index | 8 | 2019 | 1479 | 0.350 |
Why?
|
Hypoglossal Nerve Diseases | 1 | 2009 | 2 | 0.340 |
Why?
|
Dysarthria | 1 | 2009 | 7 | 0.340 |
Why?
|
Internal Capsule | 1 | 2009 | 11 | 0.340 |
Why?
|
Middle Aged | 23 | 2020 | 16310 | 0.340 |
Why?
|
Tongue | 1 | 2009 | 15 | 0.330 |
Why?
|
Movement Disorders | 1 | 2009 | 22 | 0.330 |
Why?
|
Acute Disease | 6 | 2009 | 658 | 0.330 |
Why?
|
Hospitalization | 1 | 2016 | 1290 | 0.310 |
Why?
|
Female | 30 | 2020 | 30719 | 0.310 |
Why?
|
Aspirin | 2 | 2007 | 167 | 0.310 |
Why?
|
Telemedicine | 2 | 2014 | 307 | 0.310 |
Why?
|
Heart Failure | 1 | 2016 | 853 | 0.300 |
Why?
|
Hypertension | 3 | 2016 | 568 | 0.300 |
Why?
|
Predictive Value of Tests | 6 | 2020 | 1027 | 0.300 |
Why?
|
Magnetic Resonance Imaging | 7 | 2024 | 2052 | 0.300 |
Why?
|
Tomography, X-Ray Computed | 6 | 2014 | 1507 | 0.290 |
Why?
|
Aged, 80 and over | 12 | 2020 | 5119 | 0.280 |
Why?
|
Alzheimer Disease | 5 | 2009 | 679 | 0.270 |
Why?
|
Coronary Angiography | 1 | 2007 | 176 | 0.270 |
Why?
|
White Matter | 2 | 2019 | 114 | 0.270 |
Why?
|
Brain | 4 | 2017 | 1488 | 0.260 |
Why?
|
Cerebrovascular Circulation | 2 | 2012 | 174 | 0.260 |
Why?
|
Risk Factors | 8 | 2020 | 4986 | 0.260 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2006 | 42 | 0.260 |
Why?
|
Polysomnography | 1 | 2006 | 55 | 0.250 |
Why?
|
Cardiac Catheterization | 1 | 2007 | 253 | 0.250 |
Why?
|
Cerebral Hemorrhage | 5 | 2017 | 85 | 0.250 |
Why?
|
Cognition Disorders | 2 | 2005 | 215 | 0.250 |
Why?
|
Sleep Wake Disorders | 1 | 2006 | 65 | 0.240 |
Why?
|
Encephalomyelitis, Eastern Equine | 1 | 2024 | 2 | 0.240 |
Why?
|
Treatment Outcome | 10 | 2020 | 5281 | 0.230 |
Why?
|
Retrospective Studies | 12 | 2024 | 6069 | 0.230 |
Why?
|
Peptide Fragments | 2 | 2007 | 400 | 0.230 |
Why?
|
HIV-1 | 5 | 2001 | 692 | 0.220 |
Why?
|
Presenilin-1 | 4 | 2009 | 57 | 0.220 |
Why?
|
Ticlopidine | 1 | 2003 | 45 | 0.210 |
Why?
|
Injections, Intravenous | 4 | 2009 | 155 | 0.210 |
Why?
|
Antihypertensive Agents | 1 | 2004 | 162 | 0.210 |
Why?
|
Disintegrins | 1 | 2022 | 4 | 0.200 |
Why?
|
ADAMTS13 Protein | 1 | 2022 | 6 | 0.200 |
Why?
|
Thrombospondins | 1 | 2022 | 6 | 0.200 |
Why?
|
Antifungal Agents | 2 | 1993 | 120 | 0.190 |
Why?
|
Cholesterol | 3 | 2009 | 252 | 0.190 |
Why?
|
Receptors, CXCR4 | 1 | 2001 | 34 | 0.190 |
Why?
|
Th2 Cells | 1 | 2001 | 99 | 0.190 |
Why?
|
Receptors, CCR5 | 1 | 2001 | 56 | 0.190 |
Why?
|
Models, Biological | 1 | 2006 | 1143 | 0.180 |
Why?
|
Algorithms | 1 | 2006 | 974 | 0.180 |
Why?
|
Incidence | 2 | 2019 | 1238 | 0.180 |
Why?
|
Th1 Cells | 1 | 2001 | 177 | 0.180 |
Why?
|
Hematoma | 2 | 2019 | 68 | 0.170 |
Why?
|
Time Factors | 6 | 2019 | 3615 | 0.170 |
Why?
|
Bed Rest | 1 | 2019 | 10 | 0.170 |
Why?
|
Vitamin K | 1 | 2019 | 14 | 0.160 |
Why?
|
Secondary Prevention | 3 | 2006 | 151 | 0.160 |
Why?
|
Intracranial Hemorrhages | 1 | 2019 | 61 | 0.160 |
Why?
|
Mechanical Thrombolysis | 1 | 2019 | 35 | 0.160 |
Why?
|
Leukoencephalopathies | 1 | 2019 | 24 | 0.150 |
Why?
|
Heterozygote | 3 | 2009 | 161 | 0.150 |
Why?
|
Dementia | 2 | 2003 | 248 | 0.150 |
Why?
|
Neuropsychological Tests | 2 | 1996 | 371 | 0.140 |
Why?
|
Prevalence | 3 | 2020 | 1253 | 0.140 |
Why?
|
Recombinant Proteins | 3 | 2020 | 689 | 0.130 |
Why?
|
Occipital Lobe | 1 | 1996 | 17 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2016 | 35 | 0.130 |
Why?
|
India | 2 | 2014 | 150 | 0.130 |
Why?
|
California | 1 | 2016 | 161 | 0.130 |
Why?
|
Meningeal Neoplasms | 1 | 1996 | 58 | 0.130 |
Why?
|
Cerebrum | 1 | 2015 | 16 | 0.130 |
Why?
|
Time-to-Treatment | 1 | 2016 | 98 | 0.120 |
Why?
|
Glioblastoma | 2 | 1998 | 155 | 0.120 |
Why?
|
Endovascular Procedures | 3 | 2017 | 608 | 0.120 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2015 | 111 | 0.120 |
Why?
|
Survival Analysis | 2 | 2007 | 554 | 0.120 |
Why?
|
Clodronic Acid | 1 | 1994 | 4 | 0.110 |
Why?
|
Amphotericin B | 1 | 1994 | 21 | 0.110 |
Why?
|
Risk Assessment | 4 | 2020 | 1925 | 0.110 |
Why?
|
Phagocytes | 1 | 1994 | 50 | 0.110 |
Why?
|
Brain Neoplasms | 2 | 1998 | 305 | 0.110 |
Why?
|
Patient Selection | 1 | 2016 | 465 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2017 | 902 | 0.110 |
Why?
|
Prognosis | 3 | 2009 | 1597 | 0.110 |
Why?
|
Length of Stay | 1 | 2017 | 776 | 0.110 |
Why?
|
Lethal Dose 50 | 4 | 1994 | 14 | 0.110 |
Why?
|
Phosphatidic Acids | 1 | 1993 | 7 | 0.110 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2014 | 70 | 0.100 |
Why?
|
Recurrence | 2 | 2005 | 602 | 0.100 |
Why?
|
Mannose | 1 | 1993 | 21 | 0.100 |
Why?
|
Cognition | 1 | 1996 | 454 | 0.100 |
Why?
|
Aspergillus fumigatus | 1 | 1993 | 52 | 0.100 |
Why?
|
Liposomes | 4 | 1994 | 100 | 0.100 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2020 | 145 | 0.100 |
Why?
|
Tetanus | 1 | 1991 | 5 | 0.100 |
Why?
|
Mutation | 4 | 2009 | 2456 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 931 | 0.090 |
Why?
|
Spinal Cord Compression | 1 | 1991 | 28 | 0.090 |
Why?
|
Macrophage Activation | 1 | 1992 | 118 | 0.090 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 515 | 0.090 |
Why?
|
Cohort Studies | 2 | 2019 | 2375 | 0.090 |
Why?
|
Mice, Inbred BALB C | 4 | 1994 | 868 | 0.090 |
Why?
|
Follow-Up Studies | 2 | 2007 | 2338 | 0.090 |
Why?
|
Phagocytosis | 1 | 1992 | 260 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2004 | 677 | 0.090 |
Why?
|
Delivery of Health Care | 1 | 2014 | 411 | 0.090 |
Why?
|
Efferent Pathways | 1 | 2009 | 13 | 0.080 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2009 | 26 | 0.080 |
Why?
|
Edema | 1 | 1989 | 42 | 0.080 |
Why?
|
Peripheral Nerves | 1 | 1989 | 30 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 1091 | 0.080 |
Why?
|
Adult | 9 | 2019 | 15679 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2013 | 453 | 0.080 |
Why?
|
Macrophages | 2 | 1993 | 1015 | 0.080 |
Why?
|
Eye | 1 | 1989 | 52 | 0.080 |
Why?
|
Hand | 1 | 2009 | 67 | 0.080 |
Why?
|
Regression Analysis | 2 | 2014 | 486 | 0.080 |
Why?
|
Injections, Intra-Arterial | 1 | 2009 | 20 | 0.080 |
Why?
|
Odds Ratio | 2 | 2016 | 747 | 0.080 |
Why?
|
Plant Oils | 1 | 1989 | 56 | 0.080 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 1022 | 0.080 |
Why?
|
Polyenes | 3 | 1993 | 4 | 0.080 |
Why?
|
Muscles | 1 | 1989 | 173 | 0.080 |
Why?
|
Hyperparathyroidism | 1 | 1988 | 7 | 0.080 |
Why?
|
Virus Replication | 3 | 2001 | 305 | 0.080 |
Why?
|
Reproducibility of Results | 2 | 2019 | 1559 | 0.080 |
Why?
|
Thalamic Diseases | 1 | 1988 | 2 | 0.070 |
Why?
|
Clinical Competence | 1 | 2013 | 682 | 0.070 |
Why?
|
Antiviral Agents | 3 | 1996 | 313 | 0.070 |
Why?
|
Muscular Diseases | 1 | 1988 | 46 | 0.070 |
Why?
|
Tissue Distribution | 3 | 1993 | 287 | 0.070 |
Why?
|
Electroencephalography | 2 | 2024 | 134 | 0.070 |
Why?
|
Animals | 8 | 2005 | 19649 | 0.070 |
Why?
|
Platelet Function Tests | 1 | 2007 | 10 | 0.070 |
Why?
|
Cyclooxygenase 1 | 1 | 2007 | 18 | 0.070 |
Why?
|
Thromboxane A2 | 1 | 2007 | 5 | 0.070 |
Why?
|
Platelet Activation | 1 | 2007 | 26 | 0.070 |
Why?
|
Disease Progression | 2 | 2017 | 1119 | 0.070 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2007 | 77 | 0.070 |
Why?
|
Drug Resistance | 1 | 2007 | 95 | 0.070 |
Why?
|
Pedigree | 1 | 2007 | 183 | 0.070 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 180 | 0.070 |
Why?
|
Amyloid | 1 | 2007 | 65 | 0.070 |
Why?
|
Corpus Striatum | 1 | 2007 | 93 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2004 | 284 | 0.070 |
Why?
|
Pattern Recognition, Automated | 1 | 2006 | 51 | 0.070 |
Why?
|
Intracranial Thrombosis | 1 | 2006 | 27 | 0.060 |
Why?
|
Information Storage and Retrieval | 1 | 2006 | 60 | 0.060 |
Why?
|
Cerebral Angiography | 2 | 2014 | 280 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2006 | 245 | 0.060 |
Why?
|
Ischemia | 1 | 2007 | 199 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 347 | 0.060 |
Why?
|
Drug Combinations | 2 | 2003 | 147 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 191 | 0.060 |
Why?
|
Streptokinase | 1 | 2005 | 6 | 0.060 |
Why?
|
Thrombosis | 1 | 2007 | 182 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2005 | 451 | 0.060 |
Why?
|
Expert Testimony | 1 | 2005 | 17 | 0.060 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 23 | 0.060 |
Why?
|
Encephalitis Virus, Eastern Equine | 1 | 2024 | 1 | 0.060 |
Why?
|
Family Health | 1 | 2005 | 67 | 0.060 |
Why?
|
Recovery of Function | 2 | 2019 | 270 | 0.060 |
Why?
|
Heart Diseases | 1 | 2007 | 206 | 0.060 |
Why?
|
Venous Thrombosis | 1 | 2006 | 110 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 188 | 0.060 |
Why?
|
Meta-Analysis as Topic | 1 | 2005 | 77 | 0.060 |
Why?
|
Models, Statistical | 1 | 2006 | 298 | 0.060 |
Why?
|
Cerebrovascular Disorders | 1 | 2005 | 74 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2007 | 274 | 0.060 |
Why?
|
Genetic Testing | 1 | 2005 | 126 | 0.060 |
Why?
|
Neuroprotective Agents | 1 | 2005 | 72 | 0.060 |
Why?
|
Risk | 1 | 2005 | 364 | 0.060 |
Why?
|
Anticonvulsants | 1 | 2024 | 88 | 0.060 |
Why?
|
Down-Regulation | 1 | 2005 | 305 | 0.060 |
Why?
|
tau Proteins | 1 | 2005 | 191 | 0.060 |
Why?
|
Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.060 |
Why?
|
Dipyridamole | 1 | 2003 | 17 | 0.060 |
Why?
|
Artificial Intelligence | 1 | 2006 | 154 | 0.050 |
Why?
|
Computer Simulation | 1 | 2006 | 458 | 0.050 |
Why?
|
Primary Prevention | 1 | 2004 | 134 | 0.050 |
Why?
|
Diagnostic Errors | 2 | 1996 | 94 | 0.050 |
Why?
|
Logistic Models | 2 | 2017 | 1235 | 0.050 |
Why?
|
Databases, Factual | 1 | 2006 | 814 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 805 | 0.050 |
Why?
|
Health Services | 1 | 2003 | 81 | 0.050 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 1993 | 225 | 0.050 |
Why?
|
Chemokines, CC | 1 | 2001 | 30 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2005 | 676 | 0.050 |
Why?
|
Cell Polarity | 1 | 2001 | 110 | 0.050 |
Why?
|
Drug Carriers | 2 | 1993 | 175 | 0.040 |
Why?
|
DNA, Viral | 1 | 2001 | 223 | 0.040 |
Why?
|
HIV Infections | 2 | 2000 | 913 | 0.040 |
Why?
|
Electromyography | 2 | 1991 | 88 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 163 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2005 | 850 | 0.040 |
Why?
|
Mice | 4 | 1994 | 10294 | 0.040 |
Why?
|
Cell Line | 2 | 2001 | 1983 | 0.040 |
Why?
|
Neurologic Examination | 1 | 2019 | 52 | 0.040 |
Why?
|
Hemiplegia | 1 | 1998 | 4 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2000 | 623 | 0.040 |
Why?
|
Administration, Oral | 1 | 2019 | 355 | 0.040 |
Why?
|
Radiography | 1 | 2019 | 516 | 0.040 |
Why?
|
Influenza Vaccines | 1 | 1998 | 91 | 0.040 |
Why?
|
Triage | 1 | 2017 | 108 | 0.030 |
Why?
|
Dementia, Multi-Infarct | 1 | 1996 | 4 | 0.030 |
Why?
|
Brain Abscess | 1 | 1996 | 7 | 0.030 |
Why?
|
Child | 3 | 1991 | 4187 | 0.030 |
Why?
|
Zalcitabine | 1 | 1996 | 2 | 0.030 |
Why?
|
Stavudine | 1 | 1996 | 3 | 0.030 |
Why?
|
Linear Models | 1 | 2017 | 403 | 0.030 |
Why?
|
Naphthalenesulfonates | 1 | 1996 | 1 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1996 | 116 | 0.030 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 1996 | 28 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2001 | 1465 | 0.030 |
Why?
|
Evoked Potentials, Auditory | 1 | 1995 | 10 | 0.030 |
Why?
|
Dementia, Vascular | 1 | 1995 | 7 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2000 | 651 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 1993 | 2053 | 0.030 |
Why?
|
Patient Admission | 1 | 2017 | 184 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 409 | 0.030 |
Why?
|
Patient Transfer | 1 | 2016 | 90 | 0.030 |
Why?
|
CD4 Antigens | 1 | 1996 | 148 | 0.030 |
Why?
|
Disability Evaluation | 1 | 2016 | 199 | 0.030 |
Why?
|
HIV Envelope Protein gp120 | 1 | 1996 | 130 | 0.030 |
Why?
|
Cost of Illness | 1 | 2015 | 156 | 0.030 |
Why?
|
Massachusetts | 1 | 2020 | 2019 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2017 | 255 | 0.030 |
Why?
|
Virulence | 1 | 1994 | 188 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2017 | 423 | 0.030 |
Why?
|
ROC Curve | 1 | 2014 | 267 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 1993 | 57 | 0.030 |
Why?
|
Registries | 1 | 2016 | 799 | 0.030 |
Why?
|
Endocytosis | 1 | 1992 | 149 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 651 | 0.020 |
Why?
|
Paresthesia | 1 | 1989 | 5 | 0.020 |
Why?
|
Neurons, Afferent | 1 | 1989 | 17 | 0.020 |
Why?
|
Electroretinography | 1 | 1989 | 26 | 0.020 |
Why?
|
Neural Conduction | 1 | 1989 | 29 | 0.020 |
Why?
|
Electrophysiology | 1 | 1989 | 87 | 0.020 |
Why?
|
Intraocular Pressure | 1 | 1989 | 59 | 0.020 |
Why?
|
Cell Membrane | 1 | 1992 | 486 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1992 | 428 | 0.020 |
Why?
|
Hydroxycholesterols | 1 | 2009 | 8 | 0.020 |
Why?
|
Heptanoic Acids | 1 | 2009 | 20 | 0.020 |
Why?
|
Glaucoma | 1 | 1989 | 46 | 0.020 |
Why?
|
Simvastatin | 1 | 2009 | 26 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 1989 | 102 | 0.020 |
Why?
|
Pyrroles | 1 | 2009 | 45 | 0.020 |
Why?
|
Apolipoproteins E | 1 | 2009 | 108 | 0.020 |
Why?
|
Parathyroid Glands | 1 | 1988 | 8 | 0.020 |
Why?
|
Motor Neurons | 1 | 1989 | 203 | 0.020 |
Why?
|
United States | 2 | 2015 | 7426 | 0.020 |
Why?
|
Apolipoprotein E4 | 1 | 2007 | 44 | 0.020 |
Why?
|
Preoperative Care | 1 | 1988 | 180 | 0.020 |
Why?
|
Vitamin D | 1 | 1988 | 131 | 0.020 |
Why?
|
Papilledema | 1 | 1987 | 10 | 0.020 |
Why?
|
Retinitis Pigmentosa | 1 | 1987 | 28 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 200 | 0.020 |
Why?
|
Pilot Projects | 1 | 2009 | 914 | 0.020 |
Why?
|
Calcium | 1 | 1988 | 555 | 0.010 |
Why?
|
Tennessee | 1 | 2003 | 16 | 0.010 |
Why?
|
Viral Load | 1 | 2000 | 220 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 2000 | 171 | 0.010 |
Why?
|
Adolescent | 1 | 1989 | 5835 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2000 | 153 | 0.010 |
Why?
|
Encephalomyelitis | 1 | 1998 | 5 | 0.010 |
Why?
|
Medicare | 1 | 2003 | 601 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2000 | 551 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2000 | 1189 | 0.010 |
Why?
|
Lamivudine | 1 | 1996 | 7 | 0.010 |
Why?
|
HIV Reverse Transcriptase | 1 | 1996 | 10 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 1996 | 46 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 1996 | 98 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1996 | 98 | 0.010 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 1996 | 34 | 0.010 |
Why?
|
Drug Synergism | 1 | 1996 | 132 | 0.010 |
Why?
|
HIV Seropositivity | 1 | 1996 | 82 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1994 | 471 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1994 | 495 | 0.010 |
Why?
|
Polymers | 1 | 1996 | 316 | 0.010 |
Why?
|
Rats | 1 | 1996 | 1910 | 0.010 |
Why?
|
Monocytes | 1 | 1994 | 345 | 0.010 |
Why?
|
Protein Binding | 1 | 1996 | 1555 | 0.010 |
Why?
|
Foot Deformities, Congenital | 1 | 1987 | 2 | 0.000 |
Why?
|
Hand Deformities, Congenital | 1 | 1987 | 2 | 0.000 |
Why?
|
Blindness | 1 | 1987 | 38 | 0.000 |
Why?
|
Fluorescein Angiography | 1 | 1987 | 57 | 0.000 |
Why?
|
Syndrome | 1 | 1987 | 170 | 0.000 |
Why?
|